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Introduction: Phosphatidylethanolamine (PE)-conjugated nanoliposomes were developed, 
characterized, and investigated for their accumulation in liver, kidneys, and lungs in rats.
Methods: Drug-excipient interaction was studied using Fourier transform infrared spectroscopy 
(FTIR), differential scanning calorimetry (DSC), surface morphology by field emission scanning 
electron microscopy, elemental analysis by energy dispersive X-ray (EDX) analysis, zeta potential 
and size distribution using a Zetasizer and particle size analyzer, and in vitro drug release by 
dialysis membrane. In vivo accumulation of liposomes in tissues was also studied.
Results: No chemical reaction was observed between drug and excipients. EDX study confirmed 
PE-conjugation in liposomes. Doxorubicin-loaded liposomes (DOX-L) and PE-conjugated 
  doxorubicin-loaded liposomes (DOX-PEL) were of smooth surface and homogenously dis-
tributed in nanosize range (32–37 nm) with a negative surface charge. Loading efficiencies 
were 49.25% ± 1.05% and 52.98% ± 3.22% respectively, for DOX-L and DOX-PEL. In vitro 
drug release study showed 69.91% ± 1.05% and 77.07% ± 1.02% doxorubicin released, from 
DOX-L and DOX-PEL, respectively, in nine hours. Fluorescence microscopic study showed 
that liposomes were well distributed in liver, lungs, and kidneys.
Conclusion: Data suggests that PE-conjugated nanoliposomes released the drug in a sustained 
manner and were capable of distributing them in various organs. This may be used for cell/ tissue 
targeting, attaching specific antibodies to PE.
Keywords: doxorubicin, phosphatidylethanolamine-conjugated nanoliposomes, tissue 
accumulation
Introduction
Paul Ehrlich initiated the era of development for targeted delivery when he envis-
aged a drug delivery mechanism that would target drugs directly to diseased cells. 
Since then, numerous attempts have been made to devise clinically effective targeted 
drug delivery systems. A number of carriers, utilized to carry drug at the target 
organs/  tissues have been identified, including liposomes (Doxorubicin); niosomes; 
microspheres (Doxorubicin); nanospheres (Tamoxifen citrate); erythrocytes; and 
pharmacosomes.1,2 Among those various carriers, few drug carriers have reached the 
stage of commercial formulations, where the liposomes have shown strong potential 
for effective drug delivery to the site of action. Doxil®, Myocet®, Ambisome®, and 
Depocyt® are some of the examples of Food and Drug Administration (FDA) approved 
nanosize   commercial products.3International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Cancer is a disease that is notoriously difficult to treat.4 
Cytotoxic drugs involved in treatment are designed to kill 
tumor cells, but generally also display unwanted toxicities as 
they lack tumor cell selectivity.5 Liposomes, as carriers for 
anticancer drugs, have been shown to decrease significantly 
nonspecific toxicities and to deliver an increased amount of 
drug effectively to the tumor.6 Conjugation of liposomes to a 
targeting ligand can potentially improve their selectivity for 
tumor cells. The accumulation of the liposomal drugs was 
shown to be still further improved by their specific targeting 
to the tumor, that is, by attaching certain tumor-specific mol-
ecules to the liposome surface.7 Specific vector molecules, 
such as antibodies, peptides, folate, and transferrin,8–10 are 
capable of recognizing tumors. Monoclonal antibodies were 
found to recognize specific antigens from the majority of 
known tumors, such as antibodies against ovarian cancer, 
prostate cancer, or colorectal cancer.11 Liposomes can also 
provide slow release of an encapsulated drug, resulting in 
sustained exposure to tumor cells and enhanced efficacy.12
Doxorubicin (DOX) is an antineoplastic drug of the 
anthracycline class. General properties of drugs in this class 
include interaction with deoxyribonucleic acid (DNA) in a 
variety of different ways, including intercalation (squeezing 
between the base pairs), DNA strand breakage, and inhibition 
of activity of topoisomerase II.13 Most of these compounds 
have been isolated from natural sources and antibiotics. 
  However, they lack the specificity of the antimicrobial 
  antibiotics and thus produce significant toxicity.
The anthracyclines are among the most important 
antitumor drugs available. Doxorubicin is widely used for 
the treatment of several solid tumors, while daunorubicin 
and idarubicin are used exclusively for the treatment of 
  leukemia. Doxorubicin may also inhibit polymerase activ-
ity, affect regulation of gene expression, and produce free 
radical damage to DNA. Doxorubicin possesses an antitumor 
effect against a wide spectrum of tumors, either grafted or 
spontaneous.14
Formulation scientists are engaged to exploit the 
  technological advantages of nanosciences in drug delivery 
research. Significant effort has been devoted to develop 
nanosize formulations for controlled drug delivery since it 
offers a suitable means of delivering bioactive molecules. In 
this respect, a nanodimensional drug delivery system focuses 
on formulating bioactive molecules in biocompatible nano-
systems such as drug nanocrystals, solid lipid nanoparticles, 
nanostructure lipid carriers, lipid drug conjugate nanopar-
ticles, and   nanoliposomes etc.15 This system has multifaceted 
advantages in drug delivery.
The objective of this study was to develop and evaluate 
phosphatidylethanolamine (PE)-conjugated   nanodimensional 
liposomes and to investigate the distribution of the 
  nanoliposomes in some tissues in rats. PE-conjugated anti-
body in nanoliposomes might be a useful ligand for targeted 
delivery of the drug.
Materials and methods
Materials
Doxorubicin (Doxorubicin hydrochloride) was obtained as 
gifts (Sun Pharma, Baroda, India). Soya-L-α-lecithin (SPC) 
(HiMedia Laboratories Pvt. Ltd, Mumbai, India), cholesterol 
(CHL) (Merck, Mumbai, India), phosphatidylethanolamine 
(PE) (Sigma-Aldrich, Bangalore, India), butylated hydroxy 
anisole (BHA) (Qualigens Fine Chemicals, Mumbai, India), 
and chloroform (Merck) were purchased. All other chemicals 
used were of analytical grade.
Procedure of liposome preparation
Liposomes were prepared by lipid layer hydration method.16,17 
Weighed amounts of SPC, CHL, and BHA (1% w/v) were 
taken in 250 mL round bottom flasks and were dissolved 
in chloroform. They were mixed vigorously by shaking. 
The mixture was placed in a rotary vacuum evaporator 
fitted with an A3S aspirator (Eyela, Tokyo Rikakikai Co. 
Ltd., Tokyo, Japan) and a circulating bath (Spac-N Service, 
Kolkata, India) and rotated at 150 rpm at 37°C in a water bath 
to evaporate the solvent. The flask was kept in a vacuum desi-
cator overnight for complete removal of residue of organic 
solvent. Doxorubicin (1 mg/mL) was dissolved in deionized 
water and poured into the flask containing lipid film. It was 
then hydrated at 60°C18 in a water bath fitted with a rotary 
vacuum evaporator. The flask was rotated at 100 rpm until 
the lipid film dispersed in the aqueous phase. The disper-
sion was sonicated in a bath type sonicator at a frequency 
of about 30 ± 3 KHz (Trans-o-Sonic, Mumbai, India) at the 
same temperature. After sonication, the preparation was kept 
at room temperature for about one hour for vesicle formation 
and then the preparation was stored overnight at 4°C. The 
preparation was centrifuged at 16000 rpm for one hour and 
the sample was lyophilized.17 In the case of PE-conjugated 
liposomes, weighed amounts of SPC, CHL, PE, and BHA 
were taken in 250 mL round bottom flasks and were dissolved 
in the mixture of chloroform and methanol (3:1). All other 
procedures were the same as described earlier. Fluorescent 
liposomes were prepared by the above described procedures, 
except fluorescein isothiocyanate (FITC) was dissolved in 
organic phase (mixture of chloroform and methanol).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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evaluation and characterization  
of doxorubicin-loaded liposomes  
and doxorubicin-loaded Pe liposomes
Drug-excipients interaction study:  
Fourier transform infrared (FTIR) spectroscopy
The pure drug doxorubicin (DOX), CHL, SPC, PE, and a mix-
ture of drug with CHL, SPC and a mixture of drug with CHL, 
SPC, and PE (dry powder and lyophilized   formulation) were 
mixed separately, with infrared (IR) grade potassium   bromide 
(KBr) in the ratio of 1:100. Corresponding pellets were   prepared 
by applying 5.5 metric ton pressure with a hydraulic press. 
The pellets were scanned in an inert atmosphere over a wave 
number range of 4000–400 cm-1 in a Magna IR 750 series II 
FTIR instrument (Jasco, FTIR 4200, Japan).17
Differential scanning calorimetry (Dsc)
DSC measurement of SPC was performed with an instrument 
for measurement of thermotropic transition of phospholipids 
(Mettler TA4000, Toledo, OH). Empty aluminium pans 
were used as reference and samples were carefully placed 
in another aluminium pan. The measurement was done in 
an inert atmosphere within the temperature range of 30°C to 
200°C, at 5°C per min. Differential thermal analysis (DTA) 
measurements were also performed simultaneously.
Field emission scanning electron microscopy 
(FeseM)
Morphology of liposomes was performed with the help of a 
JSM electron microscope (JEOL, Tokyo, Japan). Lyophilized 
liposome samples were reconstituted with deionized water 
and were spread on to a carbon tape over a stub. The samples 
were vacuum-dried and gold coating was applied using an ion 
sputtering device. The gold-coated samples were vacuum-
dried and examined under the electron microscope.
energy dispersive X-ray analysis (eDX analysis)
EDX is a technique used for identifying the elemental com-
position of the specimen, or an area of interest thereof. The 
EDX analysis system works as an integrated feature of a 
scanning electron microscope (SEM) (JEOL).
size distribution study and zeta potential 
measurement
Size distribution and zeta potential of the different 
  formulations were measured using a Zetasizer Nano ZS instru-
ment and analyzed using DTS software (Malvern Instruments 
Limited, Malvern, UK) using M3-PALS   technology (Malvern 
Instruments Limited), which enables accurate measurements 
of zeta potential in aqueous   dispersions. Size distribution 
and zeta potential studies were conducted by dispersing the 
samples following the guidelines of the manufacturer of the 
Zetasizer.
evaluation of doxorubicin loading
A weighed amount (5 mg) of liposomes was lysed with 
ethanol, centrifuged and the absorbance of supernatant was 
measured at 480 nm using an ultraviolet-visible (UV/VIS) 
spectrometer (Beckman Instruments, Fullerton, CA, USA). 
The same procedure was used for the batch without the drug. 
The absorbance due to drug was the difference between the 
readings obtained from the preparation with drug and with-
out drug to avoid any minor error due to the excipients. The 
loading % and the loading efficiency were calculated using 
the following formulae:19
% Loading = (amount of doxorubicin in liposomes/
amount of liposomes obtained) × 100
% Loading efficiency = (amount of doxorubicin in 
liposomes/amount of doxorubicin used in the formula-
tion) × 100
In vitro drug release study
In a 250 mL conical flask, 50 mL of phosphate-buffered saline 
(PBS) was measured.17 A weighed amount of lyophilized 
liposomes (5 mg) was reconstituted in 1 mL PBS and was 
taken into a dialysis bag (Himedia dialysis membrane-60, 
Mumbai, India). The two ends of the dialysis sac were tightly 
bound with cotton thread. The bag was hung inside the coni-
cal flask with the help of a glass rod so that the portion of 
the dialysis bag containing the formulation could dip into the 
buffer solution. The flask was kept on a magnetic stirrer. Stir-
ring was maintained at 300 rpm with the help of a magnetic 
bead at room temperature. Sampling was done by withdraw-
ing 1 mL from the released medium and 1 mL blank was 
added. The samples were analyzed in a spectrophotometer at 
480 nm. The concentration was calculated from the standard   
curve.
Liposome-accumulation in liver, kidney,  
and lungs in rats
Fluorescein isothiocyanate-phosphatidylethanolamine-
doxorubicin (FITC-PE-DOX) liposomes, PE-conjugated 
doxorubicin-loaded liposomes (DOX-PEL), and liposomes 
without drug were injected through the tail vein in differ-
ent groups of rats (n = 6).20 After one hour and three hours, 
rats were sacrificed and liver, lungs, and kidneys were International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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separated out. The organs were fixed with 10% formalin 
solution and embedded in a paraffin block. The samples were 
sectioned with a thickness of 5 µm specimen and taken on 
to the slides. The slides were dipped into xylene to remove 
the wax. After air drying, the slides were observed under 
fluorescence microscope.
statistical evaluation
The significance of the data was evaluated using Stu-
dent’s t-test (two-tailed). P values , 0.05 were considered 
significant.
Results
Preformulation study
Drug-excipients interaction study by FTIR
In this study, we have initially used FTIR spectroscopy to 
determine any drug-excipient interaction at the level of func-
tional groups. Spectra of CHL (Figure 1A), SPC (Figure 1B), 
DOX (Figure 1C), PE (Figure 1D), mixture of SPC, CHL, 
and DOX (Figure 1E), mixture of SPC, CHL, PE, and DOX 
(Figure 1F), and mixture of SPC, CHL, DOX, and PE in lyo-
philized formulation (Figure 1G) were compared at their dif-
ferent reactive functional groups in terms of peak picking.
There were mild interactions observed in wave numbers 
between 3350 cm-1 and 3450 cm-1, between 1600 cm-1 and 
1750 cm-1, and between 1050 cm-1 and 1250 cm-1. The range 
between wave numbers 3350 cm-1 and 3450 cm-1 is the char-
acteristic stretching vibration of free and bonded hydroxyl 
(OH) and amine (NH2) groups. Peak variation in the range 
may be the effect of formation of weak hydrogen bonds.24 
In fact, cholesterol, SPC, and doxorubicin had bands in the 
range between 3500 cm-1 and 3200 cm-1 and the bands were 
very close to each other. Thus the band in the range could not 
be considered as a characteristic peak for the drug. Presence 
of doxorubicin, shown in Figure 1 (F and G), was evident 
from the observed bands at 1260–1000 cm-1 (carbonyl (CO) 
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stretching of alcohol) and 900–675 cm-1 (out of plane OH 
bending).21 Spectrum band 5 of SPC-CHL-PE-DOX appeared 
stronger in comparison to that of SPC-CHL-DOX. The peak 
was indicative of the presence of SPC in the mixture. How-
ever, probably due to the variation of quantity of SPC mixing 
with KBr, a sharper peak was obtained.
The range between wave numbers 1600 cm-1 and 1750 cm-1 
is the strong intensity stretching vibration of CO, aryl ketone, 
α, β-unsaturation, and cyclo-pentanone, 1° NH2 and bending 
vibration range of medium to strong intensity NH2 scissoring 
(1° NH2 )25 and range between 1250 cm-1 and 1050 cm-1 is the 
strong intensity stretching vibration of CO, medium intensity 
stretching vibration of CN and medium intensity bending 
vibration of C-C-C bending, CH, CH2, CH3, and aromatic 
ring vibration. The drug, doxorubicin, has different reactive 
functional groups, such as free NH2 group, OH group, H, and 
CO. CHL has OH, H, and CH3 as reaction groups. SPC has 
CO, O, H, and reactive-NH2 group and PE has NH, O, and 
CO groups. Thus there may be physical interactions between 
functional groups of the drug and excipients, probably by for-
mation of weak hydrogen bond or weak bond formation due to 
van der Waals force of attraction or dipole–dipole interaction, 
etc. Since all the characteristic peaks of the drug and excipients 
were present in the drug excipient mixture (Figure 1F) and no 
predominant shifting of existing peaks or formation of new 
peaks was detected, this suggests that physical interactions took 
place only between the drug and excipients and that there was 
no chemical interaction between them. However, this has been 
further substantiated by DSC analysis of the drug, excipients, 
and their mixture. The physical interactions found here could 
be beneficial for the size and shape of the liposomes and drug 
release pattern from them.22
The data from the DSC experiments were obtained from the 
curves, by plotting heat flux against temperatures. SPC shows 
endothermic melting started at around 204°C (Figure 2B). 
In the case of the drug, endothermic melting was found to 
be at around 197°C (Figure 2D). CHL showed endothermic 
melting transition started at 40°C and at 149°C (Figure 2A). 
The initial endothermic peak could be responsible for loss of 
water and the next endothermic peak was for degradation. PE 
showed endothermic melting transition started at 105°C and 
had an endothermic peak at 125°C. One more peak close to 
140°C was observed in the case of PE (Figure 2C). Figure 2E 
provides us with a DSC curve for the mixture of PE, CHL, 
DOX, and SPC. In this curve, all the individual endothermic 
transition peaks (a, b, c, and d respectively) are predominantly 
present. This suggests that there was no chemical interaction 
between the drug and excipients.
Figure 1 Fourier transform infrared spectroscopy (FTIR) spectra of A) cholesterol (chL); B) soya-L-α-lecithin (sPc); C) doxorubicin (DOX); D) phosphatidylethanolamine 
(Pe); E) mixture of sPc, chL, and DOX; F) mixture of sPc, chL, DOX, and Pe; and G) lyophilized formulation (DOX-PeL).
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characterization of liposomes
After a thorough screening, based on physicochemical 
  characteristics, two formulations (reported here) were 
selected and subjected to further studies. PE-nongrafted 
formulations showed better yield (50%) as compared to 
PE-grafted formulations. It was found that percentage drug 
loading in doxorubicin-loaded liposomes (DOX-L) was 
2.46% and in PE-conjugated liposomes loaded with doxoru-
bicin (DOX-PEL) was 2.65%. The loading efficiencies were 
49.25% and 52.98% respectively (Table 1).
SEM photographs (Figure 3) show that the DOX-L and 
DOX-PEL had smooth surface with nano size dimension and 
were homogenously distributed. The average z-range of the 
liposomes (DOX-L and DOX-PEL) was 32–37 nm.
EDX analysis showed weight % and atomic % of various 
elements (C, O, and P) in various liposomes (Figure 4 and 
Table 2). The weight % of C, O, and P in DOX-L were 53.66, 
42.06, and 4.28 respectively; and the values for DOX-PEL 
were 46.85, 47.58, and 5.57 respectively. The atomic % of 
C, O, and P in DOX-PEL were 61.75, 36.34, and 1.91 respec-
tively; in DOX-PEL they were 55.30, 42.15, and 2.55 respec-
tively. The differences in values of weight % and atomic % 
of elements were due to the presence of PE in DOX-PEL.
About a 16% enhancement of z-average values (average 
diameter) was observed due to PE-grafting. The z-average of 
DOX-L was 32.67 nm and that of DOX-PEL was 37.84 nm 
(Figure 5). The zeta potentials for DOX-L and DOX-PEL 
were -55.6 mV and -50.2 mV respectively (Table 3). Nega-
tive surface charge was due to ionization of free groups pres-
ent on the surface of various liposomes. PE-conjugation was 
found to increase zeta potential by 10%. This may be due to 
the positive charge of PE.
In vitro release study showed that 69.91% ± 1.05% and 
77.07% ± 1.02% doxorubicin was released from DOX-L and 
DOX-PEL liposomes respectively, in nine hours (Figure 6). 
Doxorubicin release was high in the first hour of study from 
both the formulations. This could be due to the release of 
the drug from the surface or near to the surface in bilayer. 
However, the drug then released very slowly. Much slower 
drug diffusion from the core of the formulation might be 
responsible for that. Drug release from DOX-L was very slow 
till until seven hours and again it increased until the end of 
the study. In the case of DOX-PEL, drug release was found to 
be very slow between the 1st and third hour and between the 
4th and 5th hour. The reason for this is unknown. To evalu-
ate the drug-release kinetic patterns, drug-release data were 
assessed using zero order, first order, Higuchi, Korsmeyer 
and Hixson–Crowell kinetic models.25 Calculated R2 values International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Table 1 % yield, % loading and loading efficiency
Code name of the  
formulation
Molar ratio of phospholipids,  
cholesterol, and  
PE (for DOX-PEL) used
Drug: polymer  
ratio (w/w)
% yield % loading  
(mean ± SD;  
n = 3)
Loading efficiency  
(% w/w) (mean ± SD; 
n = 3)
DOX-L sPc:chL = 23.32:15.52 1:40 50 2.46 ± 0.056 49.25 ± 1.05
DOX-PeL sPc:chL:Pe = 233.2:155.2:6.7 1:41 44.72 2.65 ± 0.16 52.98 ± 3.22
Abbreviations: DOX-L, doxorubicin-loaded liposomes; DOX-PeL, Pe-conjugated doxorubicin-loaded liposomes; Pe, phosphatidylethanolamine; sPc, soya-L-α-lecithin; 
chL, cholesterol; w/w, weight/weight; sD, standard deviation.
AB
Figure 3 Field emission scanning electron microscopy (FeseM) of A) doxorubicin-
loaded liposomes (DOX-L); and B) doxorubicin-loaded Pe liposomes (DOX-PeL).
for the kinetics were tabulated (Table 4). The corresponding 
plot (log cumulative percent drug release vs. time) (data not 
shown) for the Korsmeyer equation indicated a good linear-
ity (R2 = 0.9375) for DOX-L, as compared to the others. The 
evaluation suggests that DOX-L formulations obeyed Kors-
meyer kinetics which involves a coupling of the diffusion and 
erosion mechanism. For DOX-PEL, drug release followed 
Higuchi kinetics in a better way (R2 = 0.9747), suggesting 
diffusion is the only mechanism involved in the process for 
the period of study.
Since DOX-PEL was our main interest, we have studied 
the tissue accumulation (liver, kidneys, and lungs) of them in 
rats, treating with FITC-DOX-PEL as well as DOX-PEL. Fig-
ure 7 (a–c) depicts the fluorescence microscopic photographs 
of liver, kidneys, and lungs of rats treated with FITC-DOX-
PEL (after one and three hours of treatment). Figure 8 (a–c) 
shows the fluorescence microscopic photographs of liver, kid-
neys, and lungs of rats treated with DOX-PEL. Figure 9(a–c) 
shows the fluorescence microscopic photographs of liver, 
kidneys, and lungs of rats treated with free DOX (1.5 mg/
kg), after one and three hours of treatment. Fluorescence 
intensities of FITC (Figure 7) and doxorubicin (Figures 8–9) 
were visualized. Fluorescence intensities were found to be 
more after three hours than after one hour in those tissues 
(Figure 7). This indicates that the liposome accumulation 
was gradually enhanced. Signal of fluorescein isothiocyanate 
(FITC) refers to the existence of liposomes in liver,   kidneys, 
and lungs and the results were further substantiated by visu-
alizing the fluorescence from doxorubicin, a fluorophore. 
In Figure 9, more signals (fluorescence) were observed in 
the tissues at one hour than at three. This indicates that the 
drug given intravenously was eliminated from those tissues 
quickly. As the negative and positive controls were similar 
for animal groups undergoing treatment of one and three 
hours, we have given one set of pictures for those controls 
in each case. Fluorescence microscopic study showed that 
liposomes were well distributed throughout the liver, lungs, 
and kidneys (Figures 7, 8, and 9). This study suggests that 
the experimental nanoliposomes might be useful to deliver 
the drug to those organs. Further, ligand molecule PE in the 
formulation may also be used to attach antibody conjugation 
to target specific cell type.
Discussion
Determination of drug-excipient interactions (if any), in a 
solid/semisolid dosage form, is one of the very important pre-
formulation studies which indicates the stability of the drug 
in a formulation, the drug release pattern from it, and other 
physico-chemical properties, such as surface charge, shape, 
size, etc. related to the formulation.23 There are various meth-
ods available for determination of drug-excipient interactions. 
Some of the popular and extensively-used methods to determine 
drug-excipient interactions are FTIR spectroscopy, DSC, and IR 
spectroscopy.24,25 FTIR spectroscopy showed that only physical 
interactions in some cases took place between the drug and 
excipients, which might facilitate drug loading in formulation 
and also have sustained release pattern of the drug from the 
liposomes. Various physical interactions have been reported to 
produce stable liposomes26 and claimed to be responsible factors 
of drug release, as well as shape and size of liposomes.27 Thus 
the physical interactions found here could be beneficial for the 
size and shape of the liposomes and responsible for drug release 
patterns from them. However, to confirm whether any chemical 
reaction took place, DSC study was conducted.
DSC is generally used to measure a number of character-
istic properties of a sample. It is possible to observe fusion, 
crystallization, and even oxidation and other chemical International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 4 energy dispersive X-ray (eDX) of A) doxorubicin-loaded liposomes (DOX-L); and B) doxorubicin-loaded Pe liposomes (DOX-PeL).
Table 2 Weight % and atomic % of elements in various liposomes
CK OK PK
DOX-L DOX-PEL DOX-L DOX-PEL DOX-L DOX-PEL
Weight % 53.66 46.85 42.06 47.58 4.28 5.57
Atomic % 61.75 55.30 36.34 42.15 1.91 2.55
Abbreviations: DOX-L, doxorubicin-loaded liposomes; DOX-PeL, Pe-conjugated doxorubicin-loaded liposomes; cK, carbon counts; OK, oxygen counts; PK, phosphorous 
counts.
reactions, along with the determination of glass transition 
temperature (Tg), crystallization temperature (Tc), and 
melting point (Tm) of a sample. Fluidity of lipid bi-layers 
depends on lipid or their combination used and their fluid 
gel transition temperature. The gel state (ordered) to fluid-
ity (disordered) of lipid was observed by sensitive calori-
metric instrument. The thermal transition of lipid bilayers 
was observed near 40°C. So the hydration temperature 
was kept above 40°C for formation of vesicles as reported 
earlier.28 At 60°C, it showed the best vesicular formation 
in this study. Presence of individual endothermic transi-
tion peaks of drug-excipient formulation suggests that no 
chemical interaction took place between the drug and the 
excipient molecules.
When subjected to FESEM study, homogenous distribu-
tion of nanosize liposomes was seen. Size of DOX-L and 
DOX-PEL was below 100 nm and DOX-PEL liposomes were 
generally larger in size as compared to DOX-L. This may be 
due to conjugation of PE in the liposomes, since conjugation 
of molecules in bilayer lipids has been reported to enhance 
the size of the formulation.29 Further, surface of the liposomes 
(DOX-L and DOX-PEL) was found to be smooth, suggesting 
no leakage on the formulation surface.
In EDX analysis, the difference in values of weight % 
and atomic % of elements was the proportional increase of 
the elements due to the presence of PE in DOX-PEL. This 
study suggests that PE was conjugated in liposomes.
Drug loading and drug loading efficiency were found 
to be 24.44 µg/mg and 49.25% respectively for DOX-L 
and they were 26.29 µg/mg and 52.98% respectively for 
DOX-PEL. The entrapment of drug molecules within lipid 
vesicles depends upon physico-chemical characteristics of 
drug, concentration of drug, ratio of drug to lipid, and the 
temperature at which liposome formation occurs.19 Incorpora-
tion of cholesterol at low concentration into the lipid bilayers 
of liposomes leads to an increase in trans-membrane perme-
ability, whereas incorporation of a higher amount of choles-
terol (.30%) eliminates phase-transition and decreases the 
membrane permeability.28 Cholesterol content in the experi-
mental liposomes could also be a responsible factor for the 
amounts of drug entrapment in the present study. PE-grafting 
in liposome lipid bilayers was found to enhance the drug 
loading and loading efficiency to some extent. This could 
be due to the formation of comparatively bigger liposomes 
upon PE-grafting, which might have resulted in entrapment 
of a larger quantity of drug. However, the variation of those International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
819
Phosphatidylethanolamine-conjugated nanoliposomes
data compared between the PE-grafted and PE-nongrafted 
liposomes were statistically insignificant (P . 0.05).
The size and size distribution of liposomes depend on the 
method of size reduction, by which large lipid vesicles are 
reduced to small vesicles of nanometer scale. Ultra-sonication 
helps to reduce the size of the liposomes. In this case, nano-
size liposomes may be formed as an effect of ultra-sonication. 
Ultra-sonication by bath sonication method, as compared to 
probe sonication method, has been reported to be more popu-
lar and efficient to reduce the size of the liposomes,30 since 
the energy is disseminated from all directions continuously 
for a prolonged period in the lipid suspension. After bath-
sonication, the formulations were kept for a minimum of one 
hour in the present study, to allow the fractured lipid bilayers 
to regain into small vesicles. Size and size distribution might 
depend on the ratio of SPC, cholesterol and PE used in the 
formulations, since variation in the ratio of the constituents 
was found to vary sizes (data not shown). Thus, the size range 
(32–37 nm) and narrow size distribution of liposomes, as 
assessed by   polydispersity index (PDI) values could be due to 
the specific ratio of polymers and the manufacturing process 
Table  3  size  distribution,  PDI,  and  zeta  potential  of  various 
liposomes
Average  
size  
(d nm)
PDI Zeta  
potential  
(mV)
Mobility  
(μmcm/Vs)
Conductivity   
(MS/cm)
DOX-L 32.67 0.221 -55.6 -4.36 0.0272
DOX-PeL 37.84 0.264 -50.2 -3.937 0.0356
Abbreviations: DOX-L, doxorubicin-loaded liposomes; DOX-PeL, Pe-conjugated 
doxorubicin-loaded liposomes; PDI, polydispersity index.
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Figure 6 Release of doxorubicin from doxorubicin-loaded liposomes (DOX-L) and 
doxorubicin-loaded Pe liposomes (DOX-PeL).
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Figure 5 Particle size distribution of A) doxorubicin-loaded liposomes (DOX-L); 
and B) doxorubicin-loaded Pe liposomes (DOX-PeL).
parameters used for the formulations. PDI values suggest that 
homogeneous distributions of nanoliposomes occurred in the 
case of DOX-L and DOX-PEL. However, DOX-PEL had little 
wider range of size distribution. This may be due to the pres-
ence of PE. Zeta potentials more positive than +30 mV and 
more negative than -30 mV are normally considered stable 
for colloidal dispersion.31 In our study, zeta potential values 
of both the formulations were more than -50 mV, which 
suggests that the reconstituted lyophilized nanoliposomes 
would form a stable suspension and thus would be easier for 
parenteral administration. However, PE-grafting in liposomes 
(DOX-PEL) showed less negative zeta potential value than 
that of DOX-L, due to the presence of PE (which is positively 
charged). Electrostatic and dynamic character of electrical 
double layer of liposomes is a dominant factor responsible for 
their recognition and uptake by cells. Electrostatic force in the 
liposome bilayer is easily modified by ion concentration in 
solution in which liposomes remain dispersed. Nature of sur-
face charge of liposomes and counter-ion mobility   (mobility) 
in the electrical double layer of liposomes are important 
factors for the relaxation phenomenon of electrical energy 
to cause double layer overlap.32 Electrophoretic mobility of 
liposomes to a potential at a hydrodynamic plane of shear is 
called zeta potential33 and gives us information concerning 
charge beyond the hydro-dynamically stagnant layer. On 
the other hand, conductivity gives us information about the 
amount of mobile counter charges inside the stagnant layer. 
Therefore, electrical characterization of liposomes are quanti-
fied both by measuring stream of charge matter with charge 
(zeta potential) and without charge (conductivity). Presence 
of PE in DOX-liposomes did not predominantly vary both 
mobility and conductivity data, suggesting PE-conjugation 
would not behave differently in the case of DOX-PEL for 
in vivo recognition and cellular uptake.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Table  4  In  vitro  release  kinetics  with  R2  values  for  different 
formulations
DOX-L DOX-PEL
Zero order  
kinetics
Y = 0.1134 X + 23.302  
R2 = 0.8342
Y = 0.1568 X + 22.19  
R2 = 0.9279
First order  
kinetics
Y = 0.0007 X + 1.918  
R2 = 0.8865
Y = 0.0001 X + 1.944  
R2 = 0.9705
higuchi  
kinetics
Y = 2.4371 X + 8.019  
R2 = 0.9254
Y = 3.0508 X + 3.7397  
R2 = 0.9747
Korsmeyer  
kinetics
Y = 0.3188 X + 0.9133  
R2 = 0.9375
Y = 0.382 X + 0.8022  
R2 = 0.9592
hixon–crowell  
kinetics
Y = -0.0021 X + 4.33  
R2 = 0.8766
Y = -0.0029 X + 4.4096   
R2 = 0.9666
Abbreviations: DOX-L, doxorubicin-loaded liposomes; DOX-PeL, Pe-
conjugated doxorubicin-loaded liposomes.
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Figure  7  Fluorescence  microscopic  photographs  of  a)  liver;  b)  kidneys;  and   
c) lungs of rats treated with fluorescein isothiocyanate-phosphatidylethanolamine-
doxorubicin (FITc-Pe-DOX) liposomes (A = negative control; B = positive control; 
C = one hour after treatment; D = three hours after treatment).
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(Continued)
PE-grafted liposomes showed comparatively higher 
amount of drug release in three hours as compared to the 
nongrafted ones. This may be due to the presence of PE in 
the liposomes. Presence of PE might vary the drug diffu-
sion pathways. Presence of a rigid cholesterol nucleus along 
with the acyl chain of phospholipids is known to reduce the 
freedom of motion of acyl chain, which ultimately causes the 
membrane to condense, decreases its fluidity, and acts as a 
barrier to the entrapped drug.34 Thus, presence of cholesterol 
molecules in lipid bilayers in the experimental liposomes 
might retard the drug release for a long period (nine hours). 
PE-grafting in the lipid–cholesterol liposomal membrane was 
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CD
a)
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found to release the drug in a lesser quantity (assessed by 
cumulative amount) in the first one to three hours than the PE-
nongrafted ones. However, it enhanced the drug release from 
little more than three hours until the end of this study. This 
could be due to two reasons. Firstly, PE-grafted liposomes 
were bigger in size and the size might play a role to release 
more amount of drug with time due to larger surface area 
for drug diffusion. Secondly, presence of PE might loosen 
the compactness of structure due to the increase of size and 
provide easier and simpler diffusion pathways of drug.35,36 
Drug release profile from DOX-L was best fitted with Kors-
meyer kinetics (R2 = 0.9375), indicating involvement of 
anomalous diffusion and it may indicate that the drug release 
is controlled by more than one process. In contrast, DOX-
PEL followed the Higuchi Kinetics (R2 = 0.9747), indicating 
drug diffusion from a matrix, without much involvement of 
other processes.35,36 This also suggests that PE-grafting in 
liposomes provided more structural stability as compared 
to the nongrafted one.
Doxorubicin-loaded PE-conjugated and nonconju-
gated nanoliposomes were found to accumulate in liver, 
kidneys, and lungs in rats. Since other organs were not 
assessed, we have restricted our discussion to these three 
organs only. Distribution of nanoliposomes had a similar 
distribution trend in liver, lungs, and kidneys. In the first 
hour, distribution was less and with time (three hours) it 
enhanced qualitatively (as assessed visually by fluorescence 
intensities) in all three organs. DOX-liposomes are properly 
characterized in terms of stability, loading, etc and since 
doxorubicin is fluorophore itself, we have also studied 
the FITC-free doxorubicin liposome accumulation in the 
tissues, by visualizing fluorescence of the drug in those 
Figure 8 Fluorescence microscopic photographs of liver a), kidneys b) and lungs 
c); of rats treated with phosphatidylethanolamine-doxorubicin (Pe-DOX) liposomes 
(A = negative control; B = positive control; C = one hour after treatment; D = three 
hours after treatment).
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Figure 9 Fluorescence microscopic photographs of liver a), kidneys b) and lungs 
c); of rats treated with free DOX (A = negative control; B = positive control; 
C = one hour after treatment; D = three hours after treatment).
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tissues. Fluorescence of doxorubicin was also detected in 
liver, kidneys, and lungs of experimental animals. These 
data further support the finding of the tissue accumulation 
of FITC-labeled DOX-L, as assessed by visualizing the International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
822
Rudra et al
fluorescence of FITC-labeled DOX-L which also accu-
mulated in liver, kidneys, and lungs. Stronger signals in 
tissues were also detected at three hours than those in one 
hour. Likewise, stronger signals were also seen in nine 
hours as compared to those at three hours (data not shown). 
The findings suggest the sustained drug release from lipo-
somes. Taking the advantage of nanodimension and the cell 
membrane mimicking constituents (such as phospholipids 
and PE), they might easily have entered into the cells29 and 
gradually penetration was increased. Reports suggest that 
initially, after injection, the nanodimensional carriers are 
distributed in the blood and gradually make their passage 
to the organs.29 Thus, the nanoliposomes were found to be 
suitable for easy drug distribution in the tissues and might 
provide sustained drug release there. Moreover, attaching 
antibodies (to PE) specific to particular cancer cells could 
specifically target the cell type with the nanoliposomes. 
Further studies are warranted in this area.
Conclusions
In the present study, PE-conjugated and nonconjugated 
liposomes were developed using a simple technique. They 
had an average size of 32–37 nm in a narrow size range 
and with a uniform distribution pattern. PE-grafting did 
not change the physicochemical properties of liposomes 
predominately, as compared to the PE-nongrafted formula-
tions. Drug released from the formulations in a sustained 
manner in vitro. Drug and drug-loaded liposomes in liver, 
kidneys, and lungs of rats were observed. Further, taking 
the advantage of PE-grafting, this may be used for specific 
cells or tissue targeting, attaching specific antibodies or 
other targeting molecules.
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